MBX Biosciences (MBX): JMP Securities sees nearly 500% stock potential and highlights significant unmet need in parathyroid disease

MBX Biosciences Inc. (MBX) specializes in the development of peptide therapies for the treatment of endocrine and metabolic diseases. MBX utilizes its proprietary Precision Endocrine Peptide (PEP) platform to develop innovative peptide therapeutics. The focus is on three programs. The leading candidate from MBX Biosciences is Canvuparatide (MBX 2109) – a therapy for the treatment of the rare condition known as hypoparathyroidism. In this condition, the parathyroid glands produce too little parathyroid hormone, leading to an impaired calcium...